A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Cluster headache is a disorder marked by frequent attacks of short-lasting, severe, unilateral head pain with associated autonomic symptoms. It is the most severe head pain syndrome known. Currently, the two most common treatments for cluster headaches are inhaled oxygen and injectable sumatriptan. These treatments do not work for all cluster headache patients, and patients who smoke may eventually develop contraindication to triptans. New treatment options are needed.
An alternative method of oxygen delivery (as opposed to continuous flow) uses a demand valve that is controlled by respiration rate, allowing increased oxygen flow in response to increased demand. This system may be more efficacious at stopping a cluster headache attack than the currently prescribed oxygen delivery system.
This study will compare the effectiveness of oxygen delivered via demand valve versus continuous high flow oxygen via non-rebreather face mask in the acute treatment of a cluster headache attack. All patients will treat one cluster headache with each of the 2 treatment methods.
| Condition | Intervention | Phase |
|---|---|---|
| Cluster Headache | Drug: Oxygen | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache |
- Reduction in headache pain [ Time Frame: 30 minutes ]Headache response after 30 minutes of oxygen treatment. Headache response is defined as a reduction in headache pain intensity from moderate, severe, or very severe pain to mild or no pain.
- Headache relief and pain free [ Time Frame: 5 to 60 minutes ]
- Percentage of patients with no pain after 30 minutes of treatment
- Headache relief and pain free at other time points (5 to 60 minutes)
- Reduction of autonomic symptoms at 30 minutes
- Any difference in treatment response between episodic and chronic cluster headache patients (if patient #'s allow)
- Rescue medication use
- Cluster headache recurrence by 24 hours post oxygen treatments
- Patient satisfaction with treatment response compared with prior oxygen treatment if have utilized8.Likelihood of choosing this technique again to treat a cluster headache attack
| Estimated Enrollment: | 12 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | November 2012 |
| Estimated Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Continous Flow Oxygen |
Drug: Oxygen
100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
|
| Experimental: Oxygen Demand Valve |
Drug: Oxygen
A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
|
Detailed Description:
Cluster headache is a primary headache disorder marked by frequent attacks of short-lasting, severe, unilateral head pain with associated autonomic symptoms. The goal of acute therapy for cluster headache is fast, effective and consistent relief.
In the currently recommended dosing strategy of continuous flow 100% oxygen given via a non-rebreather face mask at 7-15L/min, the time to improvement can sometimes take upwards of 20-30 minutes and is not effective for all cluster headache sufferers.
An alternative method of oxygen delivery (versus continuous flow) uses a demand valve which is controlled by the respiration rate, allowing increased oxygen flow in response to increased demand. This delivery system may be better at stopping a cluster headache attack than the continuous flow model as it can support hyperventilation which can enhance cerebral arterial vasoconstriction via a state of hyperoxia and hypocapnia. Arterial vasoconstriction is one hypothesized method by which oxygen can abort a cluster headache attack.
This proof of concept trial will evaluate if oxygen delivered via demand valve with a specific breathing technique is effective as a cluster headache acute treatment and is more effective than the traditional continuous high flow oxygen treatment with a non-rebreather face mask.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men or women 18 to 65 with history of moderate severe or very severe cluster headaches and currently in a cluster headache period or cycle are included.
Exclusion Criteria:
- Subjects who have a history of chronic obstructive lung disease, those who have major neurologic disorders other than cluster headaches, those with a history of syncope, or lightheadedness with hyperventilation and pregnant women are excluded.
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01298921
| Contact: Todd D Rozen, MD, FAAN | 570-808-6026 | tdrozen@geisinger.edu |
| United States, Pennsylvania | |
| Geisinger Wyoming Valley | Recruiting |
| Wilkes-Barre, Pennsylvania, United States, 18702 | |
| Principal Investigator: Todd D Rozen, MD, FAAN | |
| Principal Investigator: | Todd D. Rozen, MD | Geisinger Clinic |
More Information
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Geisinger Clinic |
| ClinicalTrials.gov Identifier: | NCT01298921 History of Changes |
| Other Study ID Numbers: |
2010-0205 |
| First Submitted: | February 16, 2011 |
| First Posted: | February 18, 2011 |
| Last Update Posted: | March 16, 2012 |
| Last Verified: | March 2012 |
Keywords provided by Geisinger Clinic:
|
Headache Cluster Headache Oxygen Therapy |
Additional relevant MeSH terms:
|
Headache Cluster Headache Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
Trigeminal Autonomic Cephalalgias Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases |